文献速递神经免疫神经重症与神经感染

西班牙免疫检查点抑制剂相关神经系统不良事件:一项回顾性队列研究

Neurological adverse events related to immune-checkpoint inhibitors in Spain: a retrospective cohort study.
PubMed 文献 · Lancet Neurol · 2023-01-01

该回顾性观察研究纳入西班牙20家医院的64例免疫检查点抑制剂相关神经系统不良事件患者,描述其临床特征并分析预后因素。中位年龄67岁,70%出现脑病,22%检出神经抗体。肺癌、无中枢炎症证据的脑病及心肌炎合并肌无力肌炎为死亡独立预测因素。

要点

  • 64例中70%出现脑病,22%检出神经抗体,81%累及中枢神经系统。
  • 肺癌患者死亡风险升高(HR 2.5,95%CI 1.1-6.0)。
  • 无中枢炎症证据的脑病及合并心肌炎、肌无力、肌炎者死亡风险更高(HR 5.0及6.6)。

核心结论

  • 多数神经系统免疫相关不良事件累及中枢神经系统且抗体阴性。
  • 合并心肌炎、肌无力、肌炎,或无炎症改变的脑病,或肺癌为死亡的独立预测因素。
  • 多数死亡发生于症状出现后第一个月内。
  • 若上述发现能在其他队列中重复,可证实这些患者需要早期强化治疗。

研究设计与样本

  • 回顾性观察研究,纳入西班牙20家医院2018年1月1日至2023年2月1日期间免疫检查点抑制剂使用后疑似神经系统免疫相关不良事件的83例患者,最终纳入64例。
  • 临床信息、血清和脑脊液样本在西班牙巴塞罗那医院诊所进行研究。
  • 排除已有副肿瘤综合征或神经系统症状有其他病因证据的患者。
  • 神经功能状态由治疗医生在不良事件发生后1个月评估(改善 vs 未改善),并在末次评估时评估(完全恢复或改良Rankin量表评分下降至少2分为结局良好,其他为结局不良)。
  • 采用Fisher精确检验和Mann-Whitney U检验分析临床特征,多因素logistic回归分析预后因素。

主要发现

  • 64例患者中位年龄67岁(IQR 59-74);42例(66%)男性,22例(34%)女性。
  • 主要肿瘤为肺癌30例(47%)、黑色素瘤13例(21%)、肾细胞癌7例(11%)。
  • 14例(22%)检出神经抗体;52例(81%)累及中枢神经系统,12例(19%)累及周围神经系统。
  • 脑病发生于45例(70%),其中12例(27%)有抗体或符合明确副肿瘤或自身免疫性脑炎的明确综合征,24例(53%)为无抗体或无明确综合征临床特征的脑炎,9例(20%)为无抗体且脑脊液或脑MRI无炎症改变的脑病。
  • 64例中9例(14%)合并肌无力与肌炎,其中5例合并心肌炎。

临床怎么用

  • 作者认为,若上述发现能在其他队列中重复,可证实这些患者需要早期强化治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Neurological immune-related adverse events associated with immune checkpoint inhibitors can have several clinical manifestations, but the syndromes and prognostic factors are still not well known. We aimed to characterise and group the clinical features, with a special focus in patients presenting with encephalopathy, and to identify predictors of response to therapy and survival. METHODS: This retrospective observational study included patients with neurological immune-related adverse events from 20 hospitals in Spain whose clinical information, serum samples, and CSF samples were studied at Hospital Clinic de Barcelona, Barcelona, Spain. Patients with pre-existing paraneoplastic syndromes or evidence of alternative causes for their neurological symptoms were excluded. We reviewed the clinical information, classified their clinical features, and determined the presence of neural antibodies. Neurological status was assessed by the treating physician one month after adverse event onset (as improvement vs no improvement) and at the last evaluation (complete recovery or modified Rankin Scale score decrease of at least 2 points, indicating good outcome, vs all other modified Rankin Scale scores, indicating poor outcome); if the participant had died, the date and cause of death were recorded. We used Fisher's exact tests and Mann-Whitney U tests to analyse clinical features, and multivariable logistic regression to analyse prognostic factors. FINDINGS: From Jan 1, 2018, until Feb 1, 2023, 83 patients with suspected neurological immune-related adverse events after use of immune checkpoint inhibitors were identified, of whom 64 patients were included. These patients had a median age of 67 years (IQR 59-74); 42 (66%) were male and 22 (34%) were female. The predominant tumours were lung cancer (30 [47%] patients), melanoma (13 [21%] patients), and renal cell carcinoma (seven [11%] patients). Neural antibodies were detected in 14 (22%) patients; 52 (81%) patients had CNS involvement and 12 (19%) had peripheral nervous system involvement. Encephalopathy occurred in 45 (70%) patients, 12 (27%) of whom had antibodies or well defined syndromes consistent with definite paraneoplastic or autoimmune encephalitis, 24 (53%) of whom had encephalitis without antibodies or clinical features characteristic of a defined syndrome, and nine (20%) of whom had encephalopathy without antibodies or inflammatory changes in CSF or brain MRI. Nine (14%) of 64 patients had combined myasthenia and myositis, five of them with myocarditis. Even though 58 (91%) of 64 patients received steroids and 31 (48%) of 64 received additional therapies, 18 (28%) did not improve during the first month after adverse event onset, and 11 of these 18 people died. At the last follow-up for the 53 remaining patients (median 6 months, IQR 3-13), 20 (38%) had a poor outcome (16 deaths, one related to a neurological immune-related adverse event). Mortality risk was increased in patients with lung cancer (vs those with other cancers: HR 2·5, 95% CI 1·1-6·0) and in patients with encephalopathy without evidence of CNS inflammation or combined myocarditis, myasthenia, and myositis (vs those with the remaining syndromes: HR 5·0, 1·4-17·8 and HR 6·6, 1·4-31·0, respectively). INTERPRETATION: Most neurological immune-related adverse events involved the CNS and were antibody negative. The presence of myocarditis, myasthenia, and myositis, of encephalopathy without inflammatory changes, or of lung cancer were independent predictors of death. Most deaths occurred during the first month of symptom onset. If our findings are replicated in additional cohorts, they could confirm that these patients need early and intensive treatment. FUNDING: The Instituto de Salud Carlos III and the European Union.

来源:Lancet Neurol,查看原文。版权归原作者所有。

引用

  1. Fonseca E, Cabrera-Maqueda JM, Ruiz-García R, et al. Neurological adverse events related to immune-checkpoint inhibitors in Spain: a retrospective cohort study. Lancet Neurol. 2023. PMID: 37977714. doi:10.1016/S1474-4422(23)00335-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。